Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rhabdomyosarcoma × Cyclophosphamide × Clear all

Phase

Phase 2 9 Phase 3 7 Phase 1 5 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 43 Lymphoma, Non-Hodgkin 38 Breast Neoplasms 38 Lymphoma, Large B-Cell, Diffuse 37 Precursor Cell Lymphoblastic Leukemia-Lymphoma 36 Multiple Myeloma 34 Leukemia 31 Leukemia, Lymphocytic, Chronic, B-Cell 30 Melanoma 29 Lymphoma, Follicular 25 Leukemia, Myeloid, Acute 24 Recurrence 23 Lymphoma, B-Cell 23 Lymphoma, Mantle-Cell 22 Ovarian Neoplasms 18 Neoplasm Metastasis 17 Hodgkin Disease 17 Hematologic Neoplasms 17 Pancreatic Neoplasms 16 Myelodysplastic Syndromes 16 Burkitt Lymphoma 16 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 12 Colorectal Neoplasms 12 Triple Negative Breast Neoplasms 9 Waldenstrom Macroglobulinemia 8 Uterine Cervical Neoplasms 8 Stomach Neoplasms 8 Lymphoma, Large-Cell, Immunoblastic 8

Interventions

Temozolomide 8 Irinotecan 7 Vincristine 6 Nivolumab 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 regorafenib 1 prexasertib 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 irinotecan sucrosofate 1 ganitumab 1 eribulin 1 efineptakin alfa 1 dostarlimab 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 atezolizumab 1 adavosertib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Thrombopoietin 1 Receptor Protein-Tyrosine Kinases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡